BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

DOXA AB Begins Clinical Trial Of New Orthopaedic Biomaterial


10/19/2005 5:10:17 PM

UPPSALA, Sweden, March 4 /PRNewswire/ -- DOXA AB, a Swedish biomaterials firm, announced today that it has treated its first patient utilizing its revolutionary high strength, bioactive ceramic material, which upon application, results in a complete chemical integration between the material and bone within a matter of moments. Surgeons at Akademiska University hospital in Uppsala repaired a distal radius fracture through minimally invasive injection of the DOXA material.

"The first clinical use of our material in orthopaedics represents the culmination of years of work, and a significant milestone for DOXA," commented Peter Bramberg, President and Chief Executive Officer. "These clinical trials will validate that the DOXA technology will effectively address the issues of concern with the current generation of biomaterials, and set the standard for the next."

DOXA has developed a platform of materials having superior strength, variable handling characteristics and programmable properties. The company plans to begin clinical trials for vertebral compression fractures in March, and has targeted numerous other orthopaedic and spinal applications.

DOXA AB is a privately held company focused on commercialization of next generation biomaterials, the properties of which are engineered for specific applications. Its extensive patent portfolio provides it exclusive use of a broad class of materials having extraordinary biomechanical and biochemical properties.

For more information contact: Peter Bramberg DOXA AB Axel Johanssons gata 4-7 SE-75451 Uppsala, Sweden Web address http://www.doxa.se/ / +46706673100 (phone) peter.bramberg@doxa.se (mail)

DOXA AB

CONTACT: Peter Bramberg of DOXA AB, +46706673100, orpeter.bramberg@doxa.se



Read at BioSpace.com

DOXA AB
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES